Merck & GlaxoSmithKline Competing for HPV Vaccine Market

The Philadelphia Inquirer has a piece on the competition between Merck (Gardasil) and GlaxoSmithKline (Cervarix) to come out on top in the HPV vaccine market. Cervarix is not expected to be on the market until 2008, later than the already available and heavily promoted Gardasil. The Kaiser Network has a summary.